<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MEDROL  - methylprednisolone tablet </strong><br>Stat Rx USA<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">MEDROL Tablets contain methylprednisolone which is a 
glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally 
occurring and synthetic, which are readily absorbed from the gastrointestinal 
tract. Methylprednisolone occurs as a white to practically white, odorless, 
crystalline powder. It is sparingly soluble in alcohol, in dioxane, and in 
methanol, slightly soluble in acetone, and in chloroform, and very slightly 
soluble in ether. It is practically insoluble in water.</p>
<p>The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 
11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. The 
structural formula is represented below:</p>
<br><p><img alt="Structure Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c0dd824-b099-47c3-aaf5-f6ddb873b3ee&amp;name=Medrol4_struct.jpg"></p>                                        <p>Each MEDROL Tablet for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg 
or 32 mg of methylprednisolone. </p>
<p>Inactive ingredients:</p>
<a name="i5ad6f9a0-c2ad-4710-8b0e-fa05bebd6e11"></a><table border="0" cellpadding="0" cellspacing="0" width="474">
<col width="146">
<col width="150">
<col width="178">
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">2
  mg<span> </span></span><span></span>
</td>
<td><br></td>
<td>
<span class="Bold">4 and 16 mg<span> </span></span><span></span>
</td>
</tr>
<tr>
<td>Calcium Stearate<span> </span>
</td>
<td><br></td>
<td>Calcium Stearate<span> </span>
</td>
</tr>
<tr>
<td>Corn Starch</td>
<td><br></td>
<td>
<span> </span>Corn Starch<span> </span>
</td>
</tr>
<tr>
<td>Erythrosine Sodium</td>
<td><br></td>
<td>
<span> </span>Lactose<span> </span>
</td>
</tr>
<tr>
<td>Lactose</td>
<td><br></td>
<td>
<span> </span>Mineral Oil<span> </span>
</td>
</tr>
<tr>
<td>Mineral Oil</td>
<td><br></td>
<td>
<span> </span>Sorbic Acid<span> </span>
</td>
</tr>
<tr>
<td>Sorbic Acid</td>
<td><br></td>
<td>
<span> </span>Sucrose<span> </span>
</td>
</tr>
<tr>
<td>Sucrose<span>  </span>
</td>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td>
<span class="Bold">8 and 32 mg</span><span><br></span>
</td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td>Calcium Stearate<span> </span>
</td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td>Corn Starch<span> </span>
</td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td>F D and C Yellow No. 6</td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td>Lactose<span> </span>
</td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td>Mineral Oil<span> </span>
</td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td>Sorbic Acid<span> </span>
</td>
<td><br></td>
</tr>
<tr class="Last">
<td><br></td>
<td>Sucrose<span> </span>
</td>
<td><br></td>
</tr>
</tbody>
</table>
<p></p>
<p><span class="Bold">ACTIONS</span></p>
<p>Naturally occurring glucocorticoids (hydrocortisone and 
cortisone), which also have salt-retaining properties, are used as replacement 
therapy in adrenocortical deficiency states. Their synthetic analogs are 
primarily used for their potent anti-inflammatory effects in disorders of many 
organ systems.</p>
<p>Glucocorticoids cause profound and varied metabolic effects. In addition, 
they modify the body's immune responses to diverse stimuli.</p>
<br><br><p><br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-2"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">MEDROL Tablets are indicated in the following conditions:</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>1. <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span></span><p>Primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> (hydrocortisone 
or cortisone is the first choice; synthetic analogs may be used in conjunction 
with mineralocorticoids where applicable; in infancy mineralocorticoid 
supplementation is of particular importance).</p>
<p>Congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></p>
<p>Nonsuppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span></p>
<p><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> associated with cancer</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>2. Rheumatic Disorders</span><p>As adjunctive therapy for short-term administration (to tide the 
patient over an acute episode or exacerbation) in:</p>
<p><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases 
may require low-dose maintenance therapy)</p>
<p><span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">Ankylosing spondylitis</span></p>
<p>Acute and subacute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">Synovitis</span> of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></p>
<p>Acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span></p>
<p>Post-traumatic <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></p>
<p><span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">Psoriatic arthritis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">Epicondylitis</span></p>
<p>Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span></p>
<a href="#section-"></a><a href="#section-"></a><br><span class="Bold">3. Collagen Diseases</span><p>During an exacerbation or as maintenance therapy in selected 
cases of:</p>
<p><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span></p>
<p>Systemic <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span> (<span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>)</p>
<p>Acute rheumatic carditis</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>4. Dermatologic Diseases</span><p><span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>)</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">Mycosis fungoides</span></p>
<p><span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">Pemphigus</span></p>
<p>Severe <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></p>
<a href="#section-"></a><a href="#section-"></a><br><span class="Bold">5. Allergic States</span><p>Control of severe or incapacitating allergic conditions 
intractable to adequate trials of conventional treatment:</p>
<p>Seasonal or <span class="product-label-link" type="condition" conceptid="40486433" conceptname="Perennial allergic rhinitis">perennial allergic rhinitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">Drug hypersensitivity</span> reactions</p>
<p><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span></p>
<p><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact dermatitis</span></p>
<p>Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></p>
<p><span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic dermatitis</span></p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>6. Ophthalmic Diseases</span><p>Severe acute and chronic allergic and inflammatory processes 
involving the eye and its adnexa such as:</p>
<p>Allergic corneal marginal <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span></p>
<p><span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">Herpes zoster</span> ophthalmicus</p>
<p>Anterior segment <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span></p>
<p>Diffuse posterior <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> and choroiditis</p>
<p>Sympathetic ophthalmia</p>
<p><span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">Optic neuritis</span></p>
<p><span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">Allergic conjunctivitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="434033" conceptname="Chorioretinitis">Chorioretinitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span> and <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span></p>
<a href="#section-"></a><a href="#section-"></a><br><span class="Bold">7. Respiratory Diseases</span><p>Symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span></p>
<p>Berylliosis</p>
<p>Loeffler's syndrome not manageable by other means</p>
<p>Fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently 
with appropriate antituberculous chemotherapy</p>
<p><span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonitis</span></p>
<a href="#section-"></a><a href="#section-"></a><br><span class="Bold">8. Hematologic Disorders</span><p><span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</span> in adults</p>
<p>Secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in adults</p>
<p>Acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span></p>
<p>Erythroblastopenia (RBC <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</p>
<p>Congenital (erythroid) <span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">hypoplastic anemia</span></p>
<a href="#section-"></a><a href="#section-"></a><br><span class="Bold">9. Neoplastic Diseases</span><p>For palliative management of:</p>
<p><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemias</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> in adults</p>
<p><span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">Acute leukemia</span> of childhood</p>
<a href="#section-"></a><a href="#section-"></a><br><span class="Bold">10. Edematous States</span><p>To induce a <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in the nephrotic 
syndrome, without <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, of the idiopathic type or that due to lupus 
erythematosus.</p>
<a href="#section-"></a><a href="#section-"></a><br><span class="Bold">11. Gastrointestinal Diseases</span><p>To tide the patient over a critical period of the disease in:</p>
<p><span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative colitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">Regional enteritis</span></p>
<a href="#section-"></a><a href="#section-"></a><br><span class="Bold">12. Nervous System</span><p>Acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span></p>
<a href="#section-"></a><a href="#section-"></a><br><span class="Bold">13. Miscellaneous</span><p>Tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block 
when used concurrently with appropriate antituberculous chemotherapy.</p>
<p>Trichinosis with neurologic or myocardial involvement.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-3"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-4"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients on corticosteroid therapy subjected to unusual 
stress, increased dosage of rapidly acting corticosteroids before, during, and 
after the stressful situation is indicated.</p>
<p>Corticosteroids may mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may 
appear during their use. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> with any pathogen including viral, 
bacterial, fungal, protozoan or <span class="product-label-link" type="condition" conceptid="194873" conceptname="Mixed intestinal helminthiasis">helminthic infections</span>, in any location of the 
body, may be associated with the use of corticosteroids alone or in combination 
with other immunosuppressive agents that affect cellular immunity, humoral 
immunity, or neutrophil function.<span class="Sup">1</span></p>
<p>These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may be mild, but can be severe and at times fatal. With 
increasing doses of corticosteroids, the rate of occurrence of infectious 
complications increases.<span class="Sup">2</span> There may be decreased 
resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are 
used.</p>
<p>Prolonged use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, 
<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the 
establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to fungi or viruses.</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>Usage in pregnancy</span><p>Since adequate human reproduction studies have not been done with 
corticosteroids, the use of these drugs in pregnancy, nursing mothers or women 
of child-bearing potential requires that the possible benefits of the drug be 
weighed against the potential hazards to the mother and embryo or fetus. Infants 
born of mothers who have received substantial doses of corticosteroids during 
pregnancy, should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
<a href="#section-"></a><a href="#section-"></a><p>Average and large doses of hydrocortisone or cortisone can cause 
elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion 
of potassium. These effects are less likely to occur with the synthetic 
derivatives except when used in large doses. Dietary salt restriction and 
potassium supplementation may be necessary. All corticosteroids increase calcium 
excretion.</p>
<p>Administration of live or live, attenuated vaccines is contraindicated in 
patients receiving immunosuppressive doses of corticosteroids. Killed or 
inactivated vaccines may be administered to patients receiving immunosuppressive 
doses of corticosteroids; however, the response to such vaccines may be 
diminished. Indicated immunization procedures may be undertaken in patients 
receiving nonimmunosuppressive doses of corticosteroids.</p>
<p>The use of MEDROL Tablets in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to 
those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the 
corticosteroid is used for the management of the disease in conjunction with an 
appropriate antituberculous regimen.</p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or 
tuberculin reactivity, close observation is necessary as reactivation of the 
disease may occur. During prolonged corticosteroid therapy, these patients 
should receive chemoprophylaxis.</p>
<p>Persons who are on drugs which suppress the immune system are more 
susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than healthy individuals. Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, for 
example, can have a more serious or even fatal course in non-immune children or 
adults on corticosteroids. In such children or adults who have not had these 
diseases particular care should be taken to avoid exposure. How the dose, route 
and duration of corticosteroid administration affects the risk of developing a 
disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not known. The contribution of the underlying disease 
and/or prior corticosteroid treatment to the risk is also not known. If exposed, 
to chicken pox, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be 
indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with pooled intramuscular 
immunoglobulin (IG) may be indicated. (See the respective package inserts for 
complete VZIG and IG prescribing information.) If chicken pox develops, 
treatment with antiviral agents may be considered. Similarly, corticosteroids 
should be used with great care in patients with known or suspected Strongyloides 
(threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>. In such patients, corticosteroid-induced 
<span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to Strongyloides hyperinfection and dissemination 
with widespread larval migration, often accompanied by severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and 
potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-5"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="#section-"></a><span class="Bold">General Precautions</span><p class="First">Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be 
minimized by gradual reduction of dosage. This type of relative insufficiency 
may persist for months after discontinuation of therapy; therefore, in any 
situation of stress occurring during that period, hormone therapy should be 
reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a 
mineralocorticoid should be administered concurrently.</p>
<p>There is an enhanced effect of corticosteroids on patients with 
<span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and in those with cirrhosis.</p>
<p>Corticosteroids should be used cautiously in patients with ocular herpes 
simplex because of possible <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>.</p>
<p>The lowest possible dose of corticosteroid should be used to control the 
condition under treatment, and when reduction in dosage is possible, the 
reduction should be gradual.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from 
<span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, to 
frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or 
<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
<p>Steroids should be used with caution in nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, if 
there is a probability of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> or other pyogenic 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>; fresh intestinal anastomoses; active or latent peptic 
<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>; <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>; and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span> 
gravis.</p>
<p>Growth and development of infants and children on prolonged corticosteroid 
therapy should be carefully observed.</p>
<p>Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients receiving 
corticosteroid therapy. Discontinuation of corticosteroids may result in 
clinical remission.</p>
<p>Although controlled clinical trials have shown corticosteroids to be 
effective in speeding the resolution of acute exacerbations of multiple 
sclerosis, they do not show that corticosteroids affect the ultimate outcome or 
natural history of the disease. The studies do show that relatively high doses 
of corticosteroids are necessary to demonstrate a significant effect. (See <a href="#section-"> DOSAGE AND ADMINISTRATION</a>.)</p>
<p>Since complications of treatment with glucocorticoids are dependent on the 
size of the dose and the duration of treatment, a risk/benefit decision must be 
made in each individual case as to dose and duration of treatment and as to 
whether daily or intermittent therapy should be used.</p>
<a href="#section-"></a><a href="#section-"></a><br><span class="Bold">Drug Interactions</span><p>The <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> listed below are potentially 
clinically important. Mutual inhibition of metabolism occurs with concurrent use 
of cyclosporin and methylprednisolone; therefore, it is possible that adverse 
events associated with the individual use of either drug may be more apt to 
occur. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported with concurrent use of methylprednisolone 
and cyclosporin. Drugs that induce hepatic enzymes such as phenobarbital, 
phenytoin and rifampin may increase the clearance of methylprednisolone and may 
require increases in methylprednisolone dose to achieve the desired response. 
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of 
methylprednisolone and thus decrease its clearance. Therefore, the dose of 
methylprednisolone should be titrated to avoid steroid toxicity.</p>
<p>Methylprednisolone may increase the clearance of chronic high dose aspirin. 
This could lead to decreased salicylate serum levels or increase the risk of 
salicylate toxicity when methylprednisolone is withdrawn. Aspirin should be used 
cautiously in conjunction with corticosteroids in patients suffering from 
<span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>.</p>
<p>The effect of methylprednisolone on oral anticoagulants is variable. There 
are reports of enhanced as well as diminished effects of anticoagulant when 
given concurrently with corticosteroids. Therefore, coagulation indices should 
be monitored to maintain the desired anticoagulant effect</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6"></a><p></p>
<h1>Information for the Patient</h1>
<p class="First">Persons who are on immunosuppressant doses of corticosteroids should be warned 
to avoid exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that 
if they are exposed, medical advice should be sought without delay.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Italics">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span></span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Sodium retention</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients 
</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> 
</li>
<li>Potassium loss 
</li>
<li><span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">Hypokalemic alkalosis</span> </li>
</ul>
<p><span class="Italics">Musculoskeletal</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span> 
</li>
<li>Loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">Steroid myopathy</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">Tendon rupture</span>, particularly of the Achilles tendon 
</li>
<li>Vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads 
</li>
<li>Pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones </li>
</ul>
<p><span class="Italics">Gastrointestinal</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> 
</li>
<li>Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> 
</li>
<li>Ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> </li>
</ul>
<p>Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, 
<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), and alkaline phosphatase have been observed following corticosteroid 
treatment. These changes are usually small, not associated with any clinical 
syndrome and are reversible upon discontinuation.</p>
<p><span class="Italics">Dermatologic</span></p>
<ul>
<li>Impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing 
</li>
<li><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> 
</li>
<li>May suppress reactions to skin tests 
</li>
<li>Thin fragile skin 
</li>
<li>Facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> 
</li>
<li>Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> </li>
</ul>
<p><span class="Italics">Neurological</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (pseudo-tumor cerebri) 
usually after treatment 
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </li>
</ul>
<p><span class="Italics">Endocrine</span></p>
<ul>
<li>Development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> state 
</li>
<li>Suppression of growth in children 
</li>
<li>Secondary adrenocortical and pituitary unresponsiveness, particularly in 
times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery or illness 
</li>
<li>Menstrual irregularities 
</li>
<li>Decreased carbohydrate tolerance 
</li>
<li>Manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus 
</li>
<li>Increased requirements of insulin or oral hypoglycemic agents in diabetics 
</li>
</ul>
<p><span class="Italics">Ophthalmic</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">Posterior subcapsular cataracts</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Increased intraocular pressure</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> 
</li>
<li><span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span> </li>
</ul>
<p><span class="Italics">Metabolic</span></p>
<ul><li>Negative nitrogen balance due to protein catabolism </li></ul>
<p>The following additional reactions have been reported following oral as well 
as parenteral therapy: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span> and other allergic, anaphylactic or 
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The initial dosage of MEDROL Tablets may vary from 4 mg to 48 mg 
of methylprednisolone per day depending on the specific disease entity being 
treated. In situations of less severity lower doses will generally suffice while 
in selected patients higher initial doses may be required. The initial dosage 
should be maintained or adjusted until a satisfactory response is noted. If 
after a reasonable period of time there is a lack of satisfactory clinical 
response, MEDROL should be discontinued and the patient transferred to other 
appropriate therapy.</p>
<p><span class="Bold">IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE 
VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT 
AND THE RESPONSE OF THE PATIENT.</span> After a favorable response is noted, the 
proper maintenance dosage should be determined by decreasing the initial drug 
dosage in small decrements at appropriate time intervals until the lowest dosage 
which will maintain an adequate clinical response is reached. It should be kept 
in mind that constant monitoring is needed in regard to drug dosage. Included in 
the situations which may make dosage adjustments necessary are changes in 
clinical status secondary to remissions or exacerbations in the disease process, 
the patient's individual drug responsiveness, and the effect of patient exposure 
to stressful situations not directly related to the disease entity under 
treatment; in this latter situation it may be necessary to increase the dosage 
of MEDROL for a period of time consistent with the patient's condition. If after 
long-term therapy the drug is to be stopped, it is recommended that it be 
withdrawn gradually rather than abruptly.</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold"><span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">Multiple Sclerosis</span></span><p>In treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span> daily 
doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 
1 month have been shown to be effective (4 mg of methylprednisolone is 
equivalent to 5 mg of prednisolone).</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold"><br>ADT<span class="Sup">®</span> (Alternate Day 
Therapy)</span><p>Alternate day therapy is a corticosteroid dosing regimen in which 
twice the usual daily dose of corticoid is administered every other morning. The 
purpose of this mode of therapy is to provide the patient requiring long-term 
pharmacologic dose treatment with the beneficial effects of corticoids while 
minimizing certain undesirable effects, including pituitary-adrenal suppression, 
the <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> state, corticoid withdrawal symptoms, and <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth suppression</span> in 
children.</p>
<p>The rationale for this treatment schedule is based on two major premises: (a) 
the anti-inflammatory or therapeutic effect of corticoids persists longer than 
their physical presence and metabolic effects and (b) administration of the 
corticosteroid every other morning allows for reestablishment of more nearly 
normal hypothalamic-pituitary-adrenal (HPA) activity on the off-steroid day.</p>
<p>A brief review of the HPA physiology may be helpful in understanding this 
rationale. Acting primarily through the hypothalamus a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in free cortisol 
stimulates the pituitary gland to produce increasing amounts of corticotropin 
(ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA 
system is characterized by diurnal (circadian) rhythm. Serum levels of ACTH rise 
from a low point about 10 pm to a peak level about 6 am. Increasing levels of 
ACTH stimulate adrenal cortical activity resulting in a rise in plasma cortisol 
with maximal levels occurring between 2 am and 8 am. This rise in cortisol 
dampens ACTH production and in turn adrenal cortical activity. There is a 
gradual <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in plasma corticoids during the day with lowest levels occurring 
about midnight.</p>
<p>The diurnal rhythm of the HPA axis is lost in Cushing's disease, a syndrome 
of adrenal cortical hyperfunction characterized by <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> with centripetal fat 
distribution, thinning of the skin with easy bruisability, <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">muscle wasting</span> with 
<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, 
etc. The same clinical findings of <span class="product-label-link" type="condition" conceptid="438123" conceptname="Adrenocortical hyperfunction">hyperadrenocorticism</span> may be noted during 
long-term pharmacologic dose corticoid therapy administered in conventional 
daily divided doses. It would appear, then, that a disturbance in the diurnal 
cycle with maintenance of elevated corticoid values during the night may play a 
significant role in the development of undesirable corticoid effects. Escape 
from these constantly elevated plasma levels for even short periods of time may 
be instrumental in protecting against undesirable pharmacologic effects.</p>
<p>During conventional pharmacologic dose corticosteroid therapy, ACTH 
production is inhibited with subsequent suppression of cortisol production by 
the adrenal cortex. Recovery time for normal HPA activity is variable depending 
upon the dose and duration of treatment. During this time the patient is 
vulnerable to any stressful situation. Although it has been shown that there is 
considerably less adrenal suppression following a single morning dose of 
prednisolone (10 mg) as opposed to a quarter of that dose administered every six 
hours, there is evidence that some suppressive effect on adrenal activity may be 
carried over into the following day when pharmacologic doses are used. Further, 
it has been shown that a single dose of certain corticosteroids will produce 
adrenal cortical suppression for two or more days. Other corticoids, including 
methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered 
to be short acting (producing adrenal cortical suppression for 1¼ to 1½ days 
following a single dose) and thus are recommended for alternate day therapy.</p>
<p>The following should be kept in mind when considering alternate day 
therapy:</p>
<br>1) 
Basic principles and indications for corticosteroid therapy should apply. 
The benefits of ADT should not encourage the indiscriminate use of steroids. 
<br>2) 
ADT is a therapeutic technique primarily designed for patients in whom 
long-term pharmacologic corticoid therapy is anticipated. 
<br>3) 
In less severe disease processes in which corticoid therapy is indicated, it 
may be possible to initiate treatment with ADT. More severe disease states 
usually will require daily divided high dose therapy for initial control of the 
disease process. The initial suppressive dose level should be continued until 
satisfactory clinical response is obtained, usually four to ten days in the case 
of many allergic and collagen diseases. It is important to keep the period of 
initial suppressive dose as brief as possible particularly when subsequent use 
of alternate day therapy is intended.<br>Once control has been established, two 
courses are available: (a) change to ADT and then gradually reduce the amount of 
corticoid given every other day <span class="Bold">or</span> (b) following control 
of the disease process reduce the daily dose of corticoid to the lowest 
effective level as rapidly as possible and then change over to an alternate day 
schedule. Theoretically, course (a) may be preferable. 
<br>4) 
Because of the advantages of ADT, it may be desirable to try patients on 
this form of therapy who have been on daily corticoids for long periods of time 
(eg, patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>). Since these patients may already have 
a suppressed HPA axis, establishing them on ADT may be difficult and not always 
successful. However, it is recommended that regular attempts be made to change 
them over. It may be helpful to triple or even quadruple the daily maintenance 
dose and administer this every other day rather than just doubling the daily 
dose if difficulty is encountered. Once the patient is again controlled, an 
attempt should be made to reduce this dose to a minimum. 
<br>5) 
As indicated above, certain corticosteroids, because of their prolonged 
suppressive effect on adrenal activity, are not recommended for alternate day 
therapy (eg, dexamethasone and betamethasone). 
<br>6) 
The maximal activity of the adrenal cortex is between 2 am and 8 am, and it 
is minimal between 4 pm and midnight. Exogenous corticosteroids suppress 
adrenocortical activity the least, when given at the time of maximal activity 
(am). 
<br>7) 
In using ADT it is important, as in all therapeutic situations to 
individualize and tailor the therapy to each patient. Complete control of 
symptoms will not be possible in all patients. An explanation of the benefits of 
ADT will help the patient to understand and tolerate the possible flare-up in 
symptoms which may occur in the latter part of the off-steroid day. Other 
symptomatic therapy may be added or increased at this time if needed. 
<br>8) 
In the event of an acute flare-up of the disease process, it may be 
necessary to return to a full suppressive daily divided corticoid dose for 
control. Once control is again established alternate day therapy may be 
reinstituted. 
<br>9) 
Although many of the undesirable features of corticosteroid therapy can be 
minimized by ADT, as in any therapeutic situation, the physician must carefully 
weigh the benefit-risk ratio for each patient in whom corticoid therapy is being 
considered.</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">MEDROL Tablets are available in the following strengths and 
package sizes:</p>
<p><span class="Bold">2 mg </span>(pink, elliptical, scored, imprinted MEDROL 
2)</p>
<p>  Bottles of 100                                                   NDC 
0009-0049-02</p>
<p><span class="Bold">4 mg</span> (white, elliptical, scored, imprinted MEDROL 
4)</p>
<p>  Bottles of 100                                                   NDC 
0009-0056-02</p>
<p>  Bottles of 500                                                   NDC 
0009-0056-03</p>
<p>  Unit dose packages of 100                               NDC 
0009-0056-05</p>
<p>  DOSEPAK<span class="Sup">™</span> Unit of Use (21 tablets)               NDC 
0009-0056-04</p>
<p><span class="Bold">8 mg</span> (peach, elliptical, scored, imprinted MEDROL 
8)</p>
<p>  Bottles of 25                                                     NDC 
0009-0022-01</p>
<p><span class="Bold">16 mg</span> (white, elliptical, scored, imprinted MEDROL 
16)</p>
<p>  Bottles of 50                                                     NDC 
0009-0073-01</p>
<p><span class="Bold">32 mg</span> (peach, elliptical, scored, imprinted MEDROL 
32)</p>
<p>  Bottles of 25                                                     NDC 
0009-0176-01</p>
<a href="#section-"></a><a href="#section-"></a><p>Store at controlled room temperature 20° to 25°C (68° to 77°F) 
[see USP].</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-10"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"><span class="Sup">1</span> Fekety R. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> associated with 
corticosteroids and immunosuppressive therapy. In: Gorbach SL, Bartlett JG, 
Blacklow NR, eds. <span class="Italics">Infectious Diseases</span>. Philadelphia: 
WBSaunders Company 1992:1050–1.</p>
<p><span class="Sup">2</span> Stuck AE, Minder CE, Frey FJ. Risk of infectious 
complications in patients taking glucocorticoids. <span class="Italics">Rev Infect 
Dis</span> 1989:11(6):954–63.</p>
<a href="#section-11"></a><a href="#section-11"></a><p><span class="Bold">Rx only</span></p>
<p><img alt="Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c0dd824-b099-47c3-aaf5-f6ddb873b3ee&amp;name=Pfizer_MedrolDP_image.jpg"></p>
<p><span class="Bold"></span></p>
<p>LAB-0157-3.0<br>November 2006 </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PACKAGE LABEL - MEDROL DOSEPAK - 4 MG - 21 TABS</h1>
<br><p class="First"></p>
<br><p><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c0dd824-b099-47c3-aaf5-f6ddb873b3ee&amp;name=Medrol4_Label.jpg"></p>
<p><br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MEDROL  		
					</strong><br><span class="contentTableReg">methylprednisole tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-879(NDC:0009-0056)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>methylprednisolone</strong> (methylprednisolone) </td>
<td class="formItem">methylprednisolone</td>
<td class="formItem">4 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Medrol;4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-879-21</td>
<td class="formItem">21  in 1 DOSE PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA011153</td>
<td class="formItem">10/24/1957</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Stat Rx USA
							(786036330)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>03775a4e-ac86-420f-b4b7-7d100049c85d</div>
<div>Set id: 4c0dd824-b099-47c3-aaf5-f6ddb873b3ee</div>
<div>Version: 2</div>
<div>Effective Time: 20100401</div>
</div>
</div> <div class="DistributorName">Stat Rx USA</div></p>
</body></html>
